779 results on '"Lianidou, Evi"'
Search Results
52. Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
53. Abstract 6701: 6-color Crystal Digital PCR for the high-plex detection of 10 ESR1 mutations in breast cancer
54. Data from Breast Cancer Metastasis Suppressor-1 Promoter Methylation in Primary Breast Tumors and Corresponding Circulating Tumor Cells
55. Supplementary Table 1 from Breast Cancer Metastasis Suppressor-1 Promoter Methylation in Primary Breast Tumors and Corresponding Circulating Tumor Cells
56. Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer
57. Circulating Tumor Cells: A Noninvasive Liquid Biopsy in Cancer
58. Circulating Tumor Cells and Circulating Tumor DNA
59. Contributors
60. Supplementary Table 1 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
61. Supplementary Table 3 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
62. Supplementary Figures from ESR1 Methylation: A Liquid Biopsy–Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment
63. Supplementary Table 2 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
64. Supplementary Figures S1-S2 from Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer
65. Data from ESR1 Methylation: A Liquid Biopsy–Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment
66. Supplementary Table 4 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
67. Supplementary Table 5 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
68. Corrigendum to “Delta SARS-CoV-2 variant is entirely substituted by the omicron variant during the fifth COVID-19 wave in Attica region” [Sci. Total Environ., 856(Pt 1) (2023)/159062]
69. Delta SARS-CoV-2 variant is entirely substituted by the omicron variant during the fifth COVID-19 wave in Attica region
70. Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma
71. Molecular Assays for the Detection and Characterization of CTCs
72. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA
73. Enumeration and Molecular Analysis of CTCs in Metastatic Disease: The Breast Cancer Model
74. DNA and Histone Methylation in Lung Cancer
75. Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer
76. Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
77. Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer
78. Development and Analytical Validation of a One-Step Five-Plex RT-ddPCR Assay for the Quantification of SARS-CoV-2 Transcripts in Clinical Samples
79. PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
80. Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients
81. Abstract 3384: Combined DNA methylation analysis in size based CTC fraction and matched plasma-cfDNA provides prognostic information in early stage NSCLC
82. Abstract 5158: Detection of EGFR mutations in plasma cfDNA and paired CTCs of NSCLC patients before and after osimertinib therapy using crystal digital PCR
83. Abstract 5160: Development and analytical validation of a highly sensitive and specific NAPA assay for the detection of ESR1mutations in circulating tumor cells and plasma circulating tumor DNA
84. Molecular Assays for the Detection and Molecular Characterization of CTCs
85. Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
86. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions
87. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
88. The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group “CNAPS/CTC for early detection of cancer”
89. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell’s Journey
90. Gene expression profiling and DNA methylation analyses of CTCs☆
91. The Role of CTCs as Tumor Biomarkers
92. Epigenetics and Biomarkers in Lung Cancer: Emerging Blood-Based Molecular Biomarkers for Detection and Monitoring
93. PIK3CA Hotspot Mutation Scanning by a Novel and Highly Sensitive High-Resolution Small Amplicon Melting Analysis Method
94. Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
95. DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment
96. Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
97. An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways
98. Effect of ellagic acid on the expression of human telomerase reverse transcriptase ( hTERT) α+β+ transcript in estrogen receptor-positive MCF-7 breast cancer cells
99. Prognostic significance of RASSF1A promoter methylation in operable breast cancer
100. Epigenetics and Biomarkers in Lung Cancer: Emerging Blood-Based Molecular Biomarkers for Detection and Monitoring
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.